A phase II trial of the tau antibody semorinemab indicates that it has no clinical benefit in the earliest stages of Alzheimer disease. The repeated finding that antibody-mediated reductions in protein pathology have limited or no clinical benefit indicates that we need to consider more specific or combined therapeutic targets.

中文翻译：

---

阿尔茨海默病中抗 tau 疗法的挑战

tau 抗体 semorinemab 的 II 期试验表明，它在阿尔茨海默病的早期阶段没有临床益处。反复发现抗体介导的蛋白质病理学减少具有有限或没有临床益处，这表明我们需要考虑更具体或组合的治疗靶点。